Global mRNA Therapeutics Contract Development & Manufacturing Organization Market: By Product, By Indication, By Application, By End Use, By Region & Segmental Insights Trends and Forecast, 2024 – 2034

  • Industry: Healthcare
  • Report ID: TNR-110-1158
  • Number of Pages: 420
  • Table/Charts : Yes
  • June, 2024
  • Base Year : 2024
  • No. of Companies : 10+
  • No. of Countries : 29
  • Views : 10073
  • Covid Impact Covered: Yes
  • War Impact Covered: Yes
  • Formats : PDF, Excel, PPT

An mRNA therapeutics contract development and manufacturing organization (CDMO) specializes in the comprehensive development and large-scale production of mRNA-based therapies and vaccines for pharmaceutical and biotechnology companies. These organizations offer a range of services including mRNA synthesis, purification, formulation, and aseptic filling, ensuring that the mRNA products meet stringent regulatory standards and quality controls. Leveraging advanced technologies and expertise in mRNA processes, CDMOs facilitate the rapid and efficient production of these cutting-edge therapies, enabling biotech firms to expedite their research and development timelines and bring innovative treatments to market more swiftly. The role of mRNA therapeutics CDMOs has become increasingly vital in the pharmaceutical landscape, particularly highlighted by their pivotal contribution to the mass production of COVID-19 vaccines, demonstrating their critical importance in addressing global health challenges and advancing medical science.

The rising prominence of mRNA therapeutics, particularly highlighted by the rapid development of COVID-19 vaccines, is a significant demand driver for contract development and manufacturing organizations (CDMOs) specializing in this field. The need for efficient, scalable, and high-quality production of mRNA therapeutics has skyrocketed as pharmaceutical and biotech companies recognize the technology’s potential to revolutionize treatments for a range of diseases, including infectious diseases, cancer, and genetic disorders. CDMOs provide the necessary expertise and infrastructure for mRNA synthesis, purification, and large-scale manufacturing, addressing the urgent requirement for swift product development and deployment. Additionally, the flexibility of mRNA platforms to quickly adapt to emerging pathogens and personalized medicine further fuels this demand, prompting CDMOs to expand capacities, invest in advanced technologies, and maintain stringent regulatory compliance to meet the dynamic needs of the mRNA therapeutics market. In terms of revenue, the global mRNA therapeutics contract development & manufacturing organization market was worth US$ 4.72 Bn in 2023, anticipated to witness CAGR of 12.2% during 2024 – 2034.

Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Dynamics

Growing Demand for mRNA Vaccines and Therapeutics– The COVID-19 pandemic has showcased the efficacy and speed of mRNA vaccine development, leading to increased interest in mRNA technology for various diseases. This surge in demand drives the need for specialized CDMOs capable of supporting large-scale production and rapid deployment.

Technological Advancements in mRNA Manufacturing– Innovations in mRNA synthesis, purification, and delivery systems are enhancing production efficiency and product stability. CDMOs are investing in cutting-edge technologies to stay competitive, ensuring they can meet the complex requirements of mRNA therapeutics and deliver high-quality products.

Investment in Infrastructure and Capacity Expansion– To meet the growing demand, CDMOs are expanding their manufacturing capacities and upgrading their facilities. This includes building new production lines, incorporating automation, and enhancing quality control measures, enabling them to handle larger volumes and more diverse projects.

Regulatory Compliance and Quality Assurance– The stringent regulatory landscape for mRNA therapeutics necessitates robust compliance and quality assurance protocols. CDMOs must navigate these regulations effectively to ensure their manufacturing processes meet global standards, which is critical for gaining market approval and maintaining trust with clients.

By Indication Infectious Diseases Segment had the Highest Share in the Global mRNA Therapeutics Contract Development & Manufacturing Organization Market in 2023.

The success of mRNA vaccines in combating COVID-19 has demonstrated the technology’s rapid development and deployment capabilities, making it a crucial tool in responding to infectious disease outbreaks. As a result, pharmaceutical and biotech companies are increasingly turning to CDMOs for their specialized expertise in mRNA synthesis, optimization, and large-scale production. This shift is driven by the need for swift and scalable manufacturing solutions that can meet the urgent demand for vaccines and therapeutics. Additionally, the potential to quickly adapt mRNA platforms to emerging pathogens highlights the necessity for CDMOs with cutting-edge facilities and robust quality control systems. Consequently, CDMOs are expanding their capacities and technological capabilities to cater to the growing and dynamic needs of the mRNA therapeutics market in the realm of infectious diseases.

By End Use Biotech Companies had the Highest Share in the Global mRNA Therapeutics Contract Development & Manufacturing Organization Market in 2023.

The escalating interest of biotech companies in mRNA therapeutics is markedly propelling the demand for contract development and manufacturing organizations (CDMOs). The unparalleled success of mRNA-based COVID-19 vaccines has highlighted the technology’s potential, prompting biotech firms to explore its applications across a broader spectrum, including oncology, genetic disorders, and rare diseases. This expanding therapeutic landscape necessitates sophisticated manufacturing processes, pushing biotech companies to partner with CDMOs that offer specialized expertise in mRNA synthesis, purification, and large-scale production. Additionally, the urgency to expedite time-to-market for innovative treatments underscores the need for CDMOs capable of meeting stringent regulatory standards and ensuring high-quality production. Consequently, CDMOs are witnessing a surge in demand, driving them to invest in advanced technologies and infrastructure to support the dynamic and growing needs of the biotech industry in mRNA therapeutics development.

By Region, North America Dominated the Global mRNA Therapeutics Contract Development & Manufacturing Organization Market.

The Growing demand for mRNA therapeutics in North America is significantly driving growth in the contract development and manufacturing organization (CDMO) sector. As mRNA technology proves instrumental in rapid vaccine development, particularly exemplified by the success of COVID-19 vaccines, pharmaceutical companies are increasingly relying on CDMOs for their specialized expertise and scalable manufacturing capabilities. This surge is fueled by the need for quick turnaround times, regulatory compliance, and innovative solutions in mRNA synthesis, purification, and formulation. Moreover, advancements in personalized medicine and the expanding scope of mRNA applications beyond infectious diseases to include cancer, genetic disorders, and rare diseases further amplify this demand. CDMOs are thus investing heavily in state-of-the-art facilities and technologies to meet the stringent quality and production requirements, positioning themselves as crucial partners in the biotech industry’s pursuit of groundbreaking mRNA-based treatments.

Competitive Landscape: Global mRNA Therapeutics Contract Development & Manufacturing Organization Market:

  • ApexBio Technology
  • Biocina
  • Biomay AG
  • BioNTech SE
  • Bio-Synthesis, Inc.
  • Danaher
  • eTheRNA
  • Kaneka Eurogentec S.A.
  • Lonza
  • Novo Holdings
  • Recipharm AB
  • Samsung Biologics
  • TriLink BioTechnologies
  • Other Industry Participants

 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market Scope

Report Specifications Details
Market Revenue in 2023 US$ 4.72 Bn
Market Size Forecast by 2034 US$ 16.74 Bn
Growth Rate (CAGR) 12.2%
Historic Data 2016 – 2022
Base Year for Estimation 2023
Forecast Period 2024 – 2034
Report Inclusions Market Size & Estimates, Market Dynamics, Competitive Scenario, Trends, Growth Factors, Market Determinants, Key Investment Segmentation, Product/Service/Solutions Benchmarking
Segments Covered By Product, By Indication, By Application, By End Use, By Region
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Countries Covered U.S., Canada, Mexico, Rest of North America,  France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe,  China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific,  Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,  Brazil, Argentina, Rest of Latin America
Key Players ApexBio Technology, Biocina, Biomay AG, BioNTech SE, Bio-Synthesis, Inc., Danaher, eTheRNA, Kaneka Eurogentec S.A., Lonza, Novo Holdings, Recipharm AB, Samsung Biologics, TriLink BioTechnologies.
Customization Scope Customization allows for the inclusion/modification of content pertaining to geographical regions, countries, and specific market segments.
Pricing & Procurement Options Explore purchase options tailored to your specific research requirements
Contact Details Consult With Our Expert

Japan (Toll-Free):  +81 663-386-8111

South Korea (Toll-Free):  +82-808- 703-126

Saudi Arabia (Toll-Free):  +966 800-850-1643

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

E-mail:  askanexpert@thenicheresearch.com

 

 Global mRNA Therapeutics Contract Development & Manufacturing Organization Market

By Indication

  • Infectious Diseases
  • Metabolic & Genetic Diseases
  • Cardiovascular & Cerebrovascular Diseases

By Application

  • Viral Vaccines
  • Protein Replacement Therapies
  • Cancer Immunotherapies

By End Use

  • Biotech Companies
  • Pharmaceutical Companies
  • Government & Academic Research Institutes

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

 Report Layout:

Table of Contents

.

1.Market Scope
1.1.Market Segmentation
1.2.Years Considered
1.2.1.Historic Years: 2016 – 2022
1.2.2.Base Year: 2023
1.2.3.Forecast Years: 2024 – 2034
2.Key Target Audiences
3.Research Methodology
3.1.Primary Research
3.1.1.Research Questionnaire
3.1.2.Global Percentage Breakdown
3.1.3.Primary Interviews: Key Opinion Leaders (KOLs)
3.2.Secondary Research
3.2.1.Paid Databases
3.2.2.Secondary Sources
3.3.Market Size Estimates
3.3.1.Top-Down Approach
3.3.2.Bottom-Up Approach
3.4.Data Triangulation Methodology
3.5.Research Assumptions
4.Recommendations and Insights from TNR’s Perspective**
5.Holistic Overview of MRNA Therapeutics Contract Development and Manufacturing Organization Market
6.Market Synopsis: MRNA Therapeutics Contract Development and Manufacturing Organization Market
7.MRNA Therapeutics Contract Development and Manufacturing Organization Market Analysis: Qualitative Perspective
7.1.Introduction
7.1.1.Product Definition
7.1.2.Industry Development
7.2.Market Dynamics
7.2.1.Drivers
7.2.2.Restraints
7.2.3.Opportunities
7.2.4.Challenges
7.3.Trends in MRNA Therapeutics Contract Development and Manufacturing Organization Market
7.4.Market Determinants Radar Chart
7.5.Macro-Economic and Micro-Economic Indicators: MRNA Therapeutics Contract Development and Manufacturing Organization Market
7.6.Industry Gross Margin Overview
7.7.Porter’s Five Force Analysis
7.8.Impact of Covid-19 on MRNA Therapeutics Contract Development and Manufacturing Organization Market
7.9.PESTEL Analysis
7.10.Value Chain Analysis
7.11.Pricing Analysis, By Region (2023)
7.11.1.North America
7.11.2.Europe
7.11.3.Asia Pacific
7.11.4.Middle East and Africa
7.11.5.Latin America
8.Global MRNA Therapeutics Contract Development and Manufacturing Organization Market Analysis and Forecasts, 2024 – 2034
8.1.Overview
8.1.1.Global MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn)
8.2.Global MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
8.2.1.Infectious Diseases
8.2.1.1.Definition
8.2.1.2.Market Estimation and Penetration, 2016 – 2023
8.2.1.3.Market Forecast, 2024 – 2034
8.2.1.4.Compound Annual Growth Rate (CAGR)
8.2.1.5.Regional Bifurcation
8.2.1.5.1.North America
8.2.1.5.1.1.Market Estimation, 2016 – 2023
8.2.1.5.1.2.Market Forecast, 2024 – 2034
8.2.1.5.2.Europe
8.2.1.5.2.1.Market Estimation, 2016 – 2023
8.2.1.5.2.2.Market Forecast, 2024 – 2034
8.2.1.5.3.Asia Pacific
8.2.1.5.3.1.Market Estimation, 2016 – 2023
8.2.1.5.3.2.Market Forecast, 2024 – 2034
8.2.1.5.4.Middle East and Africa
8.2.1.5.4.1.Market Estimation, 2016 – 2023
8.2.1.5.4.2.Market Forecast, 2024 – 2034
8.2.1.5.5.Latin America
8.2.1.5.5.1.Market Estimation, 2016 – 2023
8.2.1.5.5.2.Market Forecast, 2024 – 2034
8.2.2.Metabolic and Genetic Diseases
8.2.2.1.Definition
8.2.2.2.Market Estimation and Penetration, 2016 – 2023
8.2.2.3.Market Forecast, 2024 – 2034
8.2.2.4.Compound Annual Growth Rate (CAGR)
8.2.2.5.Regional Bifurcation
8.2.2.5.1.North America
8.2.2.5.1.1.Market Estimation, 2016 – 2023
8.2.2.5.1.2.Market Forecast, 2024 – 2034
8.2.2.5.2.Europe
8.2.2.5.2.1.Market Estimation, 2016 – 2023
8.2.2.5.2.2.Market Forecast, 2024 – 2034
8.2.2.5.3.Asia Pacific
8.2.2.5.3.1.Market Estimation, 2016 – 2023
8.2.2.5.3.2.Market Forecast, 2024 – 2034
8.2.2.5.4.Middle East and Africa
8.2.2.5.4.1.Market Estimation, 2016 – 2023
8.2.2.5.4.2.Market Forecast, 2024 – 2034
8.2.2.5.5.Latin America
8.2.2.5.5.1.Market Estimation, 2016 – 2023
8.2.2.5.5.2.Market Forecast, 2024 – 2034
8.2.3.Cardiovascular and Cerebrovascular Diseases
8.2.3.1.Definition
8.2.3.2.Market Estimation and Penetration, 2016 – 2023
8.2.3.3.Market Forecast, 2024 – 2034
8.2.3.4.Compound Annual Growth Rate (CAGR)
8.2.3.5.Regional Bifurcation
8.2.3.5.1.North America
8.2.3.5.1.1.Market Estimation, 2016 – 2023
8.2.3.5.1.2.Market Forecast, 2024 – 2034
8.2.3.5.2.Europe
8.2.3.5.2.1.Market Estimation, 2016 – 2023
8.2.3.5.2.2.Market Forecast, 2024 – 2034
8.2.3.5.3.Asia Pacific
8.2.3.5.3.1.Market Estimation, 2016 – 2023
8.2.3.5.3.2.Market Forecast, 2024 – 2034
8.2.3.5.4.Middle East and Africa
8.2.3.5.4.1.Market Estimation, 2016 – 2023
8.2.3.5.4.2.Market Forecast, 2024 – 2034
8.2.3.5.5.Latin America
8.2.3.5.5.1.Market Estimation, 2016 – 2023
8.2.3.5.5.2.Market Forecast, 2024 – 2034
8.3.Key Segment for Channeling Investments
8.3.1.By Indication
9.Global MRNA Therapeutics Contract Development and Manufacturing Organization Market Analysis and Forecasts, 2024 – 2034
9.1.Overview
9.2.Global MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1.Viral Vaccines
9.2.1.1.Definition
9.2.1.2.Market Estimation and Penetration, 2016 – 2023
9.2.1.3.Market Forecast, 2024 – 2034
9.2.1.4.Compound Annual Growth Rate (CAGR)
9.2.1.5.Regional Bifurcation
9.2.1.5.1.North America
9.2.1.5.1.1.Market Estimation, 2016 – 2023
9.2.1.5.1.2.Market Forecast, 2024 – 2034
9.2.1.5.2.Europe
9.2.1.5.2.1.Market Estimation, 2016 – 2023
9.2.1.5.2.2.Market Forecast, 2024 – 2034
9.2.1.5.3.Asia Pacific
9.2.1.5.3.1.Market Estimation, 2016 – 2023
9.2.1.5.3.2.Market Forecast, 2024 – 2034
9.2.1.5.4.Middle East and Africa
9.2.1.5.4.1.Market Estimation, 2016 – 2023
9.2.1.5.4.2.Market Forecast, 2024 – 2034
9.2.1.5.5.Latin America
9.2.1.5.5.1.Market Estimation, 2016 – 2023
9.2.1.5.5.2.Market Forecast, 2024 – 2034
9.2.2.Protein Replacement Therapies
9.2.2.1.Definition
9.2.2.2.Market Estimation and Penetration, 2016 – 2023
9.2.2.3.Market Forecast, 2024 – 2034
9.2.2.4.Compound Annual Growth Rate (CAGR)
9.2.2.5.Regional Bifurcation
9.2.2.5.1.North America
9.2.2.5.1.1.Market Estimation, 2016 – 2023
9.2.2.5.1.2.Market Forecast, 2024 – 2034
9.2.2.5.2.Europe
9.2.2.5.2.1.Market Estimation, 2016 – 2023
9.2.2.5.2.2.Market Forecast, 2024 – 2034
9.2.2.5.3.Asia Pacific
9.2.2.5.3.1.Market Estimation, 2016 – 2023
9.2.2.5.3.2.Market Forecast, 2024 – 2034
9.2.2.5.4.Middle East and Africa
9.2.2.5.4.1.Market Estimation, 2016 – 2023
9.2.2.5.4.2.Market Forecast, 2024 – 2034
9.2.2.5.5.Latin America
9.2.2.5.5.1.Market Estimation, 2016 – 2023
9.2.2.5.5.2.Market Forecast, 2024 – 2034
9.2.3.Cancer Immunotherapies
9.2.3.1.Definition
9.2.3.2.Market Estimation and Penetration, 2016 – 2023
9.2.3.3.Market Forecast, 2024 – 2034
9.2.3.4.Compound Annual Growth Rate (CAGR)
9.2.3.5.Regional Bifurcation
9.2.3.5.1.North America
9.2.3.5.1.1.Market Estimation, 2016 – 2023
9.2.3.5.1.2.Market Forecast, 2024 – 2034
9.2.3.5.2.Europe
9.2.3.5.2.1.Market Estimation, 2016 – 2023
9.2.3.5.2.2.Market Forecast, 2024 – 2034
9.2.3.5.3.Asia Pacific
9.2.3.5.3.1.Market Estimation, 2016 – 2023
9.2.3.5.3.2.Market Forecast, 2024 – 2034
9.2.3.5.4.Middle East and Africa
9.2.3.5.4.1.Market Estimation, 2016 – 2023
9.2.3.5.4.2.Market Forecast, 2024 – 2034
9.2.3.5.5.Latin America
9.2.3.5.5.1.Market Estimation, 2016 – 2023
9.2.3.5.5.2.Market Forecast, 2024 – 2034
9.3.Key Segment for Channeling Investments
9.3.1.By Application
10.Global MRNA Therapeutics Contract Development and Manufacturing Organization Market Analysis and Forecasts, 2024 – 2034
10.1.Overview
10.2.Global MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
10.2.1.Biotech Companies
10.2.1.1.Definition
10.2.1.2.Market Estimation and Penetration, 2016 – 2023
10.2.1.3.Market Forecast, 2024 – 2034
10.2.1.4.Compound Annual Growth Rate (CAGR)
10.2.1.5.Regional Bifurcation
10.2.1.5.1.North America
10.2.1.5.1.1.Market Estimation, 2016 – 2023
10.2.1.5.1.2.Market Forecast, 2024 – 2034
10.2.1.5.2.Europe
10.2.1.5.2.1.Market Estimation, 2016 – 2023
10.2.1.5.2.2.Market Forecast, 2024 – 2034
10.2.1.5.3.Asia Pacific
10.2.1.5.3.1.Market Estimation, 2016 – 2023
10.2.1.5.3.2.Market Forecast, 2024 – 2034
10.2.1.5.4.Middle East and Africa
10.2.1.5.4.1.Market Estimation, 2016 – 2023
10.2.1.5.4.2.Market Forecast, 2024 – 2034
10.2.1.5.5.Latin America
10.2.1.5.5.1.Market Estimation, 2016 – 2023
10.2.1.5.5.2.Market Forecast, 2024 – 2034
10.2.2.Pharmaceutical Companies
10.2.2.1.Definition
10.2.2.2.Market Estimation and Penetration, 2016 – 2023
10.2.2.3.Market Forecast, 2024 – 2034
10.2.2.4.Compound Annual Growth Rate (CAGR)
10.2.2.5.Regional Bifurcation
10.2.2.5.1.North America
10.2.2.5.1.1.Market Estimation, 2016 – 2023
10.2.2.5.1.2.Market Forecast, 2024 – 2034
10.2.2.5.2.Europe
10.2.2.5.2.1.Market Estimation, 2016 – 2023
10.2.2.5.2.2.Market Forecast, 2024 – 2034
10.2.2.5.3.Asia Pacific
10.2.2.5.3.1.Market Estimation, 2016 – 2023
10.2.2.5.3.2.Market Forecast, 2024 – 2034
10.2.2.5.4.Middle East and Africa
10.2.2.5.4.1.Market Estimation, 2016 – 2023
10.2.2.5.4.2.Market Forecast, 2024 – 2034
10.2.2.5.5.Latin America
10.2.2.5.5.1.Market Estimation, 2016 – 2023
10.2.2.5.5.2.Market Forecast, 2024 – 2034
10.2.3.Government and Academic Research Institutes
10.2.3.1.Definition
10.2.3.2.Market Estimation and Penetration, 2016 – 2023
10.2.3.3.Market Forecast, 2024 – 2034
10.2.3.4.Compound Annual Growth Rate (CAGR)
10.2.3.5.Regional Bifurcation
10.2.3.5.1.North America
10.2.3.5.1.1.Market Estimation, 2016 – 2023
10.2.3.5.1.2.Market Forecast, 2024 – 2034
10.2.3.5.2.Europe
10.2.3.5.2.1.Market Estimation, 2016 – 2023
10.2.3.5.2.2.Market Forecast, 2024 – 2034
10.2.3.5.3.Asia Pacific
10.2.3.5.3.1.Market Estimation, 2016 – 2023
10.2.3.5.3.2.Market Forecast, 2024 – 2034
10.2.3.5.4.Middle East and Africa
10.2.3.5.4.1.Market Estimation, 2016 – 2023
10.2.3.5.4.2.Market Forecast, 2024 – 2034
10.2.3.5.5.Latin America
10.2.3.5.5.1.Market Estimation, 2016 – 2023
10.2.3.5.5.2.Market Forecast, 2024 – 2034
10.3.Key Segment for Channeling Investments
10.3.1.By End Use
11.North America MRNA Therapeutics Contract Development and Manufacturing Organization Market Analysis and Forecasts, 2024 – 2034
11.1.Overview
11.1.1.North America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn)
11.2.North America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
11.2.1.Infectious Diseases
11.2.2.Metabolic and Genetic Diseases
11.2.3.Cardiovascular and Cerebrovascular Diseases
11.3.North America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
11.3.1.Viral Vaccines
11.3.2.Protein Replacement Therapies
11.3.3.Cancer Immunotherapies
11.4.North America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
11.4.1.Biotech Companies
11.4.2.Pharmaceutical Companies
11.4.3.Government and Academic Research Institutes
11.5.North America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1.U.S
11.5.1.1.U.S MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
11.5.1.1.1.Infectious Diseases
11.5.1.1.2.Metabolic and Genetic Diseases
11.5.1.1.3.Cardiovascular and Cerebrovascular Diseases
11.5.1.2.U.S MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
11.5.1.2.1.Viral Vaccines
11.5.1.2.2.Protein Replacement Therapies
11.5.1.2.3.Cancer Immunotherapies
11.5.1.3.U.S MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
11.5.1.3.1.Biotech Companies
11.5.1.3.2.Pharmaceutical Companies
11.5.1.3.3.Government and Academic Research Institutes
11.5.2.Canada
11.5.2.1.Canada MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
11.5.2.1.1.Infectious Diseases
11.5.2.1.2.Metabolic and Genetic Diseases
11.5.2.1.3.Cardiovascular and Cerebrovascular Diseases
11.5.2.2.Canada MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
11.5.2.2.1.Viral Vaccines
11.5.2.2.2.Protein Replacement Therapies
11.5.2.2.3.Cancer Immunotherapies
11.5.2.3.Canada MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
11.5.2.3.1.Biotech Companies
11.5.2.3.2.Pharmaceutical Companies
11.5.2.3.3.Government and Academic Research Institutes
11.5.3.Mexico
11.5.3.1.Mexico MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
11.5.3.1.1.Infectious Diseases
11.5.3.1.2.Metabolic and Genetic Diseases
11.5.3.1.3.Cardiovascular and Cerebrovascular Diseases
11.5.3.2.Mexico MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
11.5.3.2.1.Viral Vaccines
11.5.3.2.2.Protein Replacement Therapies
11.5.3.2.3.Cancer Immunotherapies
11.5.3.3.Mexico MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
11.5.3.3.1.Biotech Companies
11.5.3.3.2.Pharmaceutical Companies
11.5.3.3.3.Government and Academic Research Institutes
11.5.4.Rest of North America
11.5.4.1.Rest of North America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
11.5.4.1.1.Infectious Diseases
11.5.4.1.2.Metabolic and Genetic Diseases
11.5.4.1.3.Cardiovascular and Cerebrovascular Diseases
11.5.4.2.Rest of North America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
11.5.4.2.1.Viral Vaccines
11.5.4.2.2.Protein Replacement Therapies
11.5.4.2.3.Cancer Immunotherapies
11.5.4.3.Rest of North America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
11.5.4.3.1.Biotech Companies
11.5.4.3.2.Pharmaceutical Companies
11.5.4.3.3.Government and Academic Research Institutes
11.6.Key Segment for Channeling Investments
11.6.1.By Country
11.6.2.By Indication
11.6.3.By Application
11.6.4.By End Use
12.Europe MRNA Therapeutics Contract Development and Manufacturing Organization Market Analysis and Forecasts, 2024 – 2034
12.1.Overview
12.1.1.Europe MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn)
12.2.Europe MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
12.2.1.Infectious Diseases
12.2.2.Metabolic and Genetic Diseases
12.2.3.Cardiovascular and Cerebrovascular Diseases
12.3.Europe MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
12.3.1.Viral Vaccines
12.3.2.Protein Replacement Therapies
12.3.3.Cancer Immunotherapies
12.4.Europe MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
12.4.1.Biotech Companies
12.4.2.Pharmaceutical Companies
12.4.3.Government and Academic Research Institutes
12.5.Europe MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1.France
12.5.1.1.France MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.1.1.1.Infectious Diseases
12.5.1.1.2.Metabolic and Genetic Diseases
12.5.1.1.3.Cardiovascular and Cerebrovascular Diseases
12.5.1.2.France MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
12.5.1.2.1.Viral Vaccines
12.5.1.2.2.Protein Replacement Therapies
12.5.1.2.3.Cancer Immunotherapies
12.5.1.3.France MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
12.5.1.3.1.Biotech Companies
12.5.1.3.2.Pharmaceutical Companies
12.5.1.3.3.Government and Academic Research Institutes
12.5.2.The UK
12.5.2.1.The UK MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.2.1.1.Infectious Diseases
12.5.2.1.2.Metabolic and Genetic Diseases
12.5.2.1.3.Cardiovascular and Cerebrovascular Diseases
12.5.2.2.The UK MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
12.5.2.2.1.Viral Vaccines
12.5.2.2.2.Protein Replacement Therapies
12.5.2.2.3.Cancer Immunotherapies
12.5.2.3.The UK MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
12.5.2.3.1.Biotech Companies
12.5.2.3.2.Pharmaceutical Companies
12.5.2.3.3.Government and Academic Research Institutes
12.5.3.Spain
12.5.3.1.Spain MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.3.1.1.Infectious Diseases
12.5.3.1.2.Metabolic and Genetic Diseases
12.5.3.1.3.Cardiovascular and Cerebrovascular Diseases
12.5.3.2.Spain MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
12.5.3.2.1.Viral Vaccines
12.5.3.2.2.Protein Replacement Therapies
12.5.3.2.3.Cancer Immunotherapies
12.5.3.3.Spain MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
12.5.3.3.1.Biotech Companies
12.5.3.3.2.Pharmaceutical Companies
12.5.3.3.3.Government and Academic Research Institutes
12.5.4.Germany
12.5.4.1.Germany MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.4.1.1.Infectious Diseases
12.5.4.1.2.Metabolic and Genetic Diseases
12.5.4.1.3.Cardiovascular and Cerebrovascular Diseases
12.5.4.2.Germany MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
12.5.4.2.1.Viral Vaccines
12.5.4.2.2.Protein Replacement Therapies
12.5.4.2.3.Cancer Immunotherapies
12.5.4.3.Germany MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
12.5.4.3.1.Biotech Companies
12.5.4.3.2.Pharmaceutical Companies
12.5.4.3.3.Government and Academic Research Institutes
12.5.5.Italy
12.5.5.1.Italy MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.5.1.1.Infectious Diseases
12.5.5.1.2.Metabolic and Genetic Diseases
12.5.5.1.3.Cardiovascular and Cerebrovascular Diseases
12.5.5.2.Italy MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
12.5.5.2.1.Viral Vaccines
12.5.5.2.2.Protein Replacement Therapies
12.5.5.2.3.Cancer Immunotherapies
12.5.5.3.Italy MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
12.5.5.3.1.Biotech Companies
12.5.5.3.2.Pharmaceutical Companies
12.5.5.3.3.Government and Academic Research Institutes
12.5.6.Nordic Countries
12.5.6.1.Nordic Countries MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.6.1.1.Infectious Diseases
12.5.6.1.2.Metabolic and Genetic Diseases
12.5.6.1.3.Cardiovascular and Cerebrovascular Diseases
12.5.6.2.Nordic Countries MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
12.5.6.2.1.Viral Vaccines
12.5.6.2.2.Protein Replacement Therapies
12.5.6.2.3.Cancer Immunotherapies
12.5.6.3.Nordic Countries MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
12.5.6.3.1.Biotech Companies
12.5.6.3.2.Pharmaceutical Companies
12.5.6.3.3.Government and Academic Research Institutes
12.5.6.4.Nordic Countries MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1.Denmark
12.5.6.4.2.Finland
12.5.6.4.3.Iceland
12.5.6.4.4.Sweden
12.5.6.4.5.Norway
12.5.7.Benelux Union
12.5.7.1.Benelux Union MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.7.1.1.Infectious Diseases
12.5.7.1.2.Metabolic and Genetic Diseases
12.5.7.1.3.Cardiovascular and Cerebrovascular Diseases
12.5.7.2.Benelux Union MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
12.5.7.2.1.Viral Vaccines
12.5.7.2.2.Protein Replacement Therapies
12.5.7.2.3.Cancer Immunotherapies
12.5.7.3.Benelux Union MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
12.5.7.3.1.Biotech Companies
12.5.7.3.2.Pharmaceutical Companies
12.5.7.3.3.Government and Academic Research Institutes
12.5.7.4.Benelux Union MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1.Belgium
12.5.7.4.2.The Netherlands
12.5.7.4.3.Luxembourg
12.5.8.Rest of Europe
12.5.8.1.Rest of Europe MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
12.5.8.1.1.Infectious Diseases
12.5.8.1.2.Metabolic and Genetic Diseases
12.5.8.1.3.Cardiovascular and Cerebrovascular Diseases
12.5.8.2.Rest of Europe MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
12.5.8.2.1.Viral Vaccines
12.5.8.2.2.Protein Replacement Therapies
12.5.8.2.3.Cancer Immunotherapies
12.5.8.3.Rest of Europe MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
12.5.8.3.1.Biotech Companies
12.5.8.3.2.Pharmaceutical Companies
12.5.8.3.3.Government and Academic Research Institutes
12.6.Key Segment for Channeling Investments
12.6.1.By Country
12.6.2.By Indication
12.6.3.By Application
12.6.4.By End Use
13.Asia Pacific MRNA Therapeutics Contract Development and Manufacturing Organization Market Analysis and Forecasts, 2024 – 2034
13.1.Overview
13.1.1.Asia Pacific MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn)
13.2.Asia Pacific MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
13.2.1.Infectious Diseases
13.2.2.Metabolic and Genetic Diseases
13.2.3.Cardiovascular and Cerebrovascular Diseases
13.3.Asia Pacific MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
13.3.1.Viral Vaccines
13.3.2.Protein Replacement Therapies
13.3.3.Cancer Immunotherapies
13.4.Asia Pacific MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
13.4.1.Biotech Companies
13.4.2.Pharmaceutical Companies
13.4.3.Government and Academic Research Institutes
13.5.Asia Pacific MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1.China
13.5.1.1.China MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.1.1.1.Infectious Diseases
13.5.1.1.2.Metabolic and Genetic Diseases
13.5.1.1.3.Cardiovascular and Cerebrovascular Diseases
13.5.1.2.China MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1.2.1.Viral Vaccines
13.5.1.2.2.Protein Replacement Therapies
13.5.1.2.3.Cancer Immunotherapies
13.5.1.3.China MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
13.5.1.3.1.Biotech Companies
13.5.1.3.2.Pharmaceutical Companies
13.5.1.3.3.Government and Academic Research Institutes
13.5.2.Japan
13.5.2.1.Japan MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.2.1.1.Infectious Diseases
13.5.2.1.2.Metabolic and Genetic Diseases
13.5.2.1.3.Cardiovascular and Cerebrovascular Diseases
13.5.2.2.Japan MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
13.5.2.2.1.Viral Vaccines
13.5.2.2.2.Protein Replacement Therapies
13.5.2.2.3.Cancer Immunotherapies
13.5.2.3.Japan MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
13.5.2.3.1.Biotech Companies
13.5.2.3.2.Pharmaceutical Companies
13.5.2.3.3.Government and Academic Research Institutes
13.5.3.India
13.5.3.1.India MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.3.1.1.Infectious Diseases
13.5.3.1.2.Metabolic and Genetic Diseases
13.5.3.1.3.Cardiovascular and Cerebrovascular Diseases
13.5.3.2.India MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
13.5.3.2.1.Viral Vaccines
13.5.3.2.2.Protein Replacement Therapies
13.5.3.2.3.Cancer Immunotherapies
13.5.3.3.India MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
13.5.3.3.1.Biotech Companies
13.5.3.3.2.Pharmaceutical Companies
13.5.3.3.3.Government and Academic Research Institutes
13.5.4.New Zealand
13.5.4.1.New Zealand MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.4.1.1.Infectious Diseases
13.5.4.1.2.Metabolic and Genetic Diseases
13.5.4.1.3.Cardiovascular and Cerebrovascular Diseases
13.5.4.2.New Zealand MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
13.5.4.2.1.Viral Vaccines
13.5.4.2.2.Protein Replacement Therapies
13.5.4.2.3.Cancer Immunotherapies
13.5.4.3.New Zealand MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
13.5.4.3.1.Biotech Companies
13.5.4.3.2.Pharmaceutical Companies
13.5.4.3.3.Government and Academic Research Institutes
13.5.5.Australia
13.5.5.1.Australia MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.5.1.1.Infectious Diseases
13.5.5.1.2.Metabolic and Genetic Diseases
13.5.5.1.3.Cardiovascular and Cerebrovascular Diseases
13.5.5.2.Australia MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
13.5.5.2.1.Viral Vaccines
13.5.5.2.2.Protein Replacement Therapies
13.5.5.2.3.Cancer Immunotherapies
13.5.5.3.Australia MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
13.5.5.3.1.Biotech Companies
13.5.5.3.2.Pharmaceutical Companies
13.5.5.3.3.Government and Academic Research Institutes
13.5.6.South Korea
13.5.6.1.South Korea MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.6.1.1.Infectious Diseases
13.5.6.1.2.Metabolic and Genetic Diseases
13.5.6.1.3.Cardiovascular and Cerebrovascular Diseases
13.5.6.2.South Korea MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
13.5.6.2.1.Viral Vaccines
13.5.6.2.2.Protein Replacement Therapies
13.5.6.2.3.Cancer Immunotherapies
13.5.6.3.South Korea MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
13.5.6.3.1.Biotech Companies
13.5.6.3.2.Pharmaceutical Companies
13.5.6.3.3.Government and Academic Research Institutes
13.5.7.Southeast Asia
13.5.7.1.Southeast Asia MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.7.1.1.Infectious Diseases
13.5.7.1.2.Metabolic and Genetic Diseases
13.5.7.1.3.Cardiovascular and Cerebrovascular Diseases
13.5.7.2.Southeast Asia MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
13.5.7.2.1.Viral Vaccines
13.5.7.2.2.Protein Replacement Therapies
13.5.7.2.3.Cancer Immunotherapies
13.5.7.3.Southeast Asia MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
13.5.7.3.1.Biotech Companies
13.5.7.3.2.Pharmaceutical Companies
13.5.7.3.3.Government and Academic Research Institutes
13.5.7.4.Southeast Asia MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1.Indonesia
13.5.7.4.2.Thailand
13.5.7.4.3.Malaysia
13.5.7.4.4.Singapore
13.5.7.4.5.Rest of Southeast Asia
13.5.8.Rest of Asia Pacific
13.5.8.1.Rest of Asia Pacific MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
13.5.8.1.1.Infectious Diseases
13.5.8.1.2.Metabolic and Genetic Diseases
13.5.8.1.3.Cardiovascular and Cerebrovascular Diseases
13.5.8.2.Rest of Asia Pacific MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
13.5.8.2.1.Viral Vaccines
13.5.8.2.2.Protein Replacement Therapies
13.5.8.2.3.Cancer Immunotherapies
13.5.8.3.Rest of Asia Pacific MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
13.5.8.3.1.Biotech Companies
13.5.8.3.2.Pharmaceutical Companies
13.5.8.3.3.Government and Academic Research Institutes
13.6.Key Segment for Channeling Investments
13.6.1.By Country
13.6.2.By Indication
13.6.3.By Application
13.6.4.By End Use
14.Middle East and Africa MRNA Therapeutics Contract Development and Manufacturing Organization Market Analysis and Forecasts, 2024 – 2034
14.1.Overview
14.1.1.Middle East and Africa MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn)
14.2.Middle East and Africa MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
14.2.1.Infectious Diseases
14.2.2.Metabolic and Genetic Diseases
14.2.3.Cardiovascular and Cerebrovascular Diseases
14.3.Middle East and Africa MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
14.3.1.Viral Vaccines
14.3.2.Protein Replacement Therapies
14.3.3.Cancer Immunotherapies
14.4.Middle East and Africa MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
14.4.1.Biotech Companies
14.4.2.Pharmaceutical Companies
14.4.3.Government and Academic Research Institutes
14.5.Middle East and Africa MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1.Saudi Arabia
14.5.1.1.Saudi Arabia MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.1.1.1.Infectious Diseases
14.5.1.1.2.Metabolic and Genetic Diseases
14.5.1.1.3.Cardiovascular and Cerebrovascular Diseases
14.5.1.2.Saudi Arabia MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
14.5.1.2.1.Viral Vaccines
14.5.1.2.2.Protein Replacement Therapies
14.5.1.2.3.Cancer Immunotherapies
14.5.1.3.Saudi Arabia MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
14.5.1.3.1.Biotech Companies
14.5.1.3.2.Pharmaceutical Companies
14.5.1.3.3.Government and Academic Research Institutes
14.5.2.UAE
14.5.2.1.UAE MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.2.1.1.Infectious Diseases
14.5.2.1.2.Metabolic and Genetic Diseases
14.5.2.1.3.Cardiovascular and Cerebrovascular Diseases
14.5.2.2.UAE MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
14.5.2.2.1.Viral Vaccines
14.5.2.2.2.Protein Replacement Therapies
14.5.2.2.3.Cancer Immunotherapies
14.5.2.3.UAE MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
14.5.2.3.1.Biotech Companies
14.5.2.3.2.Pharmaceutical Companies
14.5.2.3.3.Government and Academic Research Institutes
14.5.3.Egypt
14.5.3.1.Egypt MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.3.1.1.Infectious Diseases
14.5.3.1.2.Metabolic and Genetic Diseases
14.5.3.1.3.Cardiovascular and Cerebrovascular Diseases
14.5.3.2.Egypt MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
14.5.3.2.1.Viral Vaccines
14.5.3.2.2.Protein Replacement Therapies
14.5.3.2.3.Cancer Immunotherapies
14.5.3.3.Egypt MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
14.5.3.3.1.Biotech Companies
14.5.3.3.2.Pharmaceutical Companies
14.5.3.3.3.Government and Academic Research Institutes
14.5.4.Kuwait
14.5.4.1.Kuwait MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.4.1.1.Infectious Diseases
14.5.4.1.2.Metabolic and Genetic Diseases
14.5.4.1.3.Cardiovascular and Cerebrovascular Diseases
14.5.4.2.Kuwait MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
14.5.4.2.1.Viral Vaccines
14.5.4.2.2.Protein Replacement Therapies
14.5.4.2.3.Cancer Immunotherapies
14.5.4.3.Kuwait MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
14.5.4.3.1.Biotech Companies
14.5.4.3.2.Pharmaceutical Companies
14.5.4.3.3.Government and Academic Research Institutes
14.5.5.South Africa
14.5.5.1.South Africa MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.5.1.1.Infectious Diseases
14.5.5.1.2.Metabolic and Genetic Diseases
14.5.5.1.3.Cardiovascular and Cerebrovascular Diseases
14.5.5.2.South Africa MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
14.5.5.2.1.Viral Vaccines
14.5.5.2.2.Protein Replacement Therapies
14.5.5.2.3.Cancer Immunotherapies
14.5.5.3.South Africa MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
14.5.5.3.1.Biotech Companies
14.5.5.3.2.Pharmaceutical Companies
14.5.5.3.3.Government and Academic Research Institutes
14.5.6.Rest of Middle East & Africa
14.5.6.1.Rest of Middle East & Africa MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
14.5.6.1.1.Infectious Diseases
14.5.6.1.2.Metabolic and Genetic Diseases
14.5.6.1.3.Cardiovascular and Cerebrovascular Diseases
14.5.6.2.Rest of Middle East & Africa MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
14.5.6.2.1.Viral Vaccines
14.5.6.2.2.Protein Replacement Therapies
14.5.6.2.3.Cancer Immunotherapies
14.5.6.3.Rest of Middle East & Africa MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
14.5.6.3.1.Biotech Companies
14.5.6.3.2.Pharmaceutical Companies
14.5.6.3.3.Government and Academic Research Institutes
14.6.Key Segment for Channeling Investments
14.6.1.By Country
14.6.2.By Indication
14.6.3.By Application
14.6.4.By End Use
15.Latin America MRNA Therapeutics Contract Development and Manufacturing Organization Market Analysis and Forecasts, 2024 – 2034
15.1.Overview
15.1.1.Latin America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn)
15.2.Latin America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
15.2.1.Infectious Diseases
15.2.2.Metabolic and Genetic Diseases
15.2.3.Cardiovascular and Cerebrovascular Diseases
15.3.Latin America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
15.3.1.Viral Vaccines
15.3.2.Protein Replacement Therapies
15.3.3.Cancer Immunotherapies
15.4.Latin America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
15.4.1.Biotech Companies
15.4.2.Pharmaceutical Companies
15.4.3.Government and Academic Research Institutes
15.5.Latin America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1.Brazil
15.5.1.1.Brazil MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
15.5.1.1.1.Infectious Diseases
15.5.1.1.2.Metabolic and Genetic Diseases
15.5.1.1.3.Cardiovascular and Cerebrovascular Diseases
15.5.1.2.Brazil MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1.2.1.Viral Vaccines
15.5.1.2.2.Protein Replacement Therapies
15.5.1.2.3.Cancer Immunotherapies
15.5.1.3.Brazil MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
15.5.1.3.1.Biotech Companies
15.5.1.3.2.Pharmaceutical Companies
15.5.1.3.3.Government and Academic Research Institutes
15.5.2.Argentina
15.5.2.1.Argentina MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
15.5.2.1.1.Infectious Diseases
15.5.2.1.2.Metabolic and Genetic Diseases
15.5.2.1.3.Cardiovascular and Cerebrovascular Diseases
15.5.2.2.Argentina MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
15.5.2.2.1.Viral Vaccines
15.5.2.2.2.Protein Replacement Therapies
15.5.2.2.3.Cancer Immunotherapies
15.5.2.3.Argentina MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
15.5.2.3.1.Biotech Companies
15.5.2.3.2.Pharmaceutical Companies
15.5.2.3.3.Government and Academic Research Institutes
15.5.3.Rest of Latin America
15.5.3.1.Rest of Latin America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Indication
15.5.3.1.1.Infectious Diseases
15.5.3.1.2.Metabolic and Genetic Diseases
15.5.3.1.3.Cardiovascular and Cerebrovascular Diseases
15.5.3.2.Rest of Latin America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By Application
15.5.3.2.1.Viral Vaccines
15.5.3.2.2.Protein Replacement Therapies
15.5.3.2.3.Cancer Immunotherapies
15.5.3.3.Rest of Latin America MRNA Therapeutics Contract Development and Manufacturing Organization Market Revenue (US$ Mn) and Forecasts, By End Use
15.5.3.3.1.Biotech Companies
15.5.3.3.2.Pharmaceutical Companies
15.5.3.3.3.Government and Academic Research Institutes
15.6.Key Segment for Channeling Investments
15.6.1.By Country
15.6.2.By Indication
15.6.3.By Application
15.6.4.By End Use
16.Competitive Benchmarking
16.1.Brand Benchmarking
16.2.Market Share Analysis, 2023
16.3.Global Presence and Growth Strategies
16.3.1.Mergers and Acquisitions
16.3.2.Product Launches
16.3.3.Investments Trends
16.3.4.R&D Initiatives
17.Player Profiles
17.1.ApexBio Technology
17.1.1.Company Details
17.1.2.Company Overview
17.1.3.Product Offerings
17.1.4.Key Developments
17.1.5.Financial Analysis
17.1.6.SWOT Analysis
17.1.7.Business Strategies
17.2.Biocina
17.2.1.Company Details
17.2.2.Company Overview
17.2.3.Product Offerings
17.2.4.Key Developments
17.2.5.Financial Analysis
17.2.6.SWOT Analysis
17.2.7.Business Strategies
17.3.Biomay AG
17.3.1.Company Details
17.3.2.Company Overview
17.3.3.Product Offerings
17.3.4.Key Developments
17.3.5.Financial Analysis
17.3.6.SWOT Analysis
17.3.7.Business Strategies
17.4.BioNTech SE
17.4.1.Company Details
17.4.2.Company Overview
17.4.3.Product Offerings
17.4.4.Key Developments
17.4.5.Financial Analysis
17.4.6.SWOT Analysis
17.4.7.Business Strategies
17.5.Bio-Synthesis, Inc.
17.5.1.Company Details
17.5.2.Company Overview
17.5.3.Product Offerings
17.5.4.Key Developments
17.5.5.Financial Analysis
17.5.6.SWOT Analysis
17.5.7.Business Strategies
17.6.Danaher
17.6.1.Company Details
17.6.2.Company Overview
17.6.3.Product Offerings
17.6.4.Key Developments
17.6.5.Financial Analysis
17.6.6.SWOT Analysis
17.6.7.Business Strategies
17.7.eTheRNA
17.7.1.Company Details
17.7.2.Company Overview
17.7.3.Product Offerings
17.7.4.Key Developments
17.7.5.Financial Analysis
17.7.6.SWOT Analysis
17.7.7.Business Strategies
17.8.Kaneka Eurogentec S.A.
17.8.1.Company Details
17.8.2.Company Overview
17.8.3.Product Offerings
17.8.4.Key Developments
17.8.5.Financial Analysis
17.8.6.SWOT Analysis
17.8.7.Business Strategies
17.9.Lonza
17.9.1.Company Details
17.9.2.Company Overview
17.9.3.Product Offerings
17.9.4.Key Developments
17.9.5.Financial Analysis
17.9.6.SWOT Analysis
17.9.7.Business Strategies
17.10.Novo Holdings
17.10.1.Company Details
17.10.2.Company Overview
17.10.3.Product Offerings
17.10.4.Key Developments
17.10.5.Financial Analysis
17.10.6.SWOT Analysis
17.10.7.Business Strategies
17.11.Recipharm AB
17.11.1.Company Details
17.11.2.Company Overview
17.11.3.Product Offerings
17.11.4.Key Developments
17.11.5.Financial Analysis
17.11.6.SWOT Analysis
17.11.7.Business Strategies
17.12.Samsung Biologics
17.12.1.Company Details
17.12.2.Company Overview
17.12.3.Product Offerings
17.12.4.Key Developments
17.12.5.Financial Analysis
17.12.6.SWOT Analysis
17.12.7.Business Strategies
17.13.TriLink BioTechnologies
17.13.1.Company Details
17.13.2.Company Overview
17.13.3.Product Offerings
17.13.4.Key Developments
17.13.5.Financial Analysis
17.13.6.SWOT Analysis
17.13.7.Business Strategies
17.14.Other Industry Participants
18.Key Findings

.

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

.

**Exclusive for Multi-User and Enterprise User.

Global mRNA Therapeutics Contract Development & Manufacturing Organization Market

By Indication

  • Infectious Diseases
  • Metabolic & Genetic Diseases
  • Cardiovascular & Cerebrovascular Diseases

By Application

  • Viral Vaccines
  • Protein Replacement Therapies
  • Cancer Immunotherapies

By End Use

  • Biotech Companies
  • Pharmaceutical Companies
  • Government & Academic Research Institutes

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

The Niche Research approach encompasses both primary and secondary research methods to provide comprehensive insights. While primary research is the cornerstone of our studies, we also incorporate secondary research sources such as company annual reports, premium industry databases, press releases, industry journals, and white papers.

Within our primary research, we actively engage with various industry stakeholders, conducting paid interviews and surveys. Our meticulous analysis extends to every market participant in major countries, allowing us to thoroughly examine their portfolios, calculate market shares, and segment revenues.

Our data collection primarily focuses on individual countries within our research scope, enabling us to estimate regional market sizes. Typically, we employ a bottom-up approach, meticulously tracking trends in different countries. We analyze growth drivers, constraints, technological innovations, and opportunities for each country, ultimately arriving at regional figures.Our process begins by examining the growth prospects of each country. Building upon these insights, we project growth and trends for the entire region. Finally, we utilize our proprietary model to refine estimations and forecasts.

Our data validation standards are integral to ensuring the reliability and accuracy of our research findings. Here’s a breakdown of our data validation processes and the stakeholders we engage with during our primary research:

  • Supply Side Analysis: We initiate a supply side analysis by directly contacting market participants, through telephonic interviews and questionnaires containing both open-ended and close-ended questions. We gather information on their portfolios, segment revenues, developments, and growth strategies.
  • Demand Side Analysis: To gain insights into adoption trends and consumer preferences, we reach out to target customers and users (non-vendors). This information forms a vital part of the qualitative analysis section of our reports, covering market dynamics, adoption trends, consumer behavior, spending patterns, and other related aspects.
  • Consultant Insights: We tap into the expertise of our partner consultants from around the world to obtain their unique viewpoints and perspectives. Their insights contribute to a well-rounded understanding of the markets under investigation.
  • In-House Validation: To ensure data accuracy and reliability, we conduct cross-validation of data points and information through our in-house team of consultants and utilize advanced data modeling tools for thorough verification.

The forecasts we provide are based on a comprehensive assessment of various factors, including:

  • Market Trends and Past Performance (Last Five Years): We accurately analyze market trends and performance data from preceding five years to identify historical patterns and understand the market’s evolution.
  • Historical Performance and Growth of Market Participants: We assess the historical performance and growth trajectories of key market participants. This analysis provides insights into the competitive landscape and individual company strategies.
  • Market Determinants Impact Analysis (Next Eight Years): We conduct a rigorous analysis of the factors that are projected to influence the market over the next eight years. This includes assessing both internal and external determinants that can shape market dynamics.
  • Drivers and Challenges for the Forecast Period:Identify the factors expected to drive market growth during the forecast period, as well as the challenges that the industry may face. This analysis aids in deriving an accurate growth rate projection.
  • New Acquisitions, Collaborations, or Partnerships: We keep a close watch on any new acquisitions, collaborations, or partnerships within the industry. These developments can have a significant impact on market dynamics and competitiveness.
  • Macro and Micro Factors Analysis:A thorough examination of both macro-level factors (e.g., economic trends, regulatory changes) and micro-level factors (e.g., technological advancements, consumer preferences) that may influence the market during the forecast period.
  • End-User Sentiment Analysis: To understand the market from the end-user perspective, we conduct sentiment analysis. This involves assessing the sentiment, preferences, and feedback of the end-users, which can provide valuable insights into market trends.
  • Perspective of Primary Participants: Insights gathered directly from primary research participants play a crucial role in shaping our forecasts. Their perspectives and experiences provide valuable qualitative data.
  • Year-on-Year Growth Trend: We utilize a year-on-year growth trend based on historical market growth and expected future trends. This helps in formulating our growth projections, aligning them with the market’s historical performance.

Research process adopted by TNR involves multiple stages, including data collection, validation, quality checks, and presentation. It’s crucial that the data and information we provide add value to your existing market understanding and expertise. We have also established partnerships with business consulting, research, and survey organizations across regions and globally to collaborate on regional analysis and data validation, ensuring the highest level of accuracy and reliability in our reports.

 

 

Procure Comprehensive Study of

Global mRNA Therapeutics Contract Development & Manufacturing Organization Market

Online Only

  • Online Access
  • Read Only File
  • Validity 3 Months
  • Print, Copy, Paste & Download
  • PPT, Excel
  • Cost-Free Report in the Next Update
$3300
Buy Now

Single User

  • Access to One User on One System
  • Read Only File
  • Validity 6 Months
  • Limited Print,Copy, Paste
  • PPT, Excel
  • Cost-Free Report in the Next Update
$4200
Buy Now

Multi User

  • Access to Fiver Users
  • PDF File
  • Validity 1 Year
  • Upto FivePrints
  • Cost-Free Report in the Next Update
  • PPT, Excel
$6000
Buy Now

Enterprise User

  • Access to Unlimited Users
  • PDF, PPT, Excel
  • Unlimited Validity, Prints&Downloads
  • 1 Hour Cost-Free & Dedicated Analyst Support
  • 10% Cost-Free Customization
  • Cost-Free Report Update Twice in a Year
  • Recommendations for Business Strategies
  • Authorization to Quote TNR, The Niche Research
$7300
Buy Now

Library Access

  • Online Access to Content Publications
  • Access Player Profiles Online
  • Get Immediate Access to Newly Added Content
  • Acquire 12 PDF Downloads
  • Acquire 5 Excel Data Sets
  • Gain Access to 290+ PDFs of Company Profiles
  • Round-the-clock Email and Phone Assistance
  • Dashboard Usage and Trends
  • Renewal & Upgrade Assistance
  • Assessing Customization Options and Alerts for New Reports
$10788
Buy Now
*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Why TNR The Niche Research?

  • Unwavering Commitment to Excellence

  • Veteran Team of Researchers

  • Accurate and Timely Insights

  • Ethical Practices and Customized Service

  • Uninterrupted Availability Around the Clock

Scroll to Top